Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline's Infanrix DTaP vaccine to be launched in February following FDA approval Jan. 29.

Executive Summary

SMITHKLINE INFANRIX ACELLULAR DTP VACCINE TO BE LAUNCHED IN FEBRUARY, following FDA approval Jan. 29. Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) will be the third DTaP vaccine on the market, following Wyeth-Lederle's Acel-Imune and Connaught's Tripedia. SB is bidding for a contract with the Vaccines for Children Program. New York-based GTFH will be handling advertising of Infanrix.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029657

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel